Syndax Pharmaceuticals's total assets for Q4 2024 were $724.82M, an increase of 70.22% from the previous quarter. SNDX total liabilities were $436.69M for the fiscal quarter, a 635.43% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.